BioSpace News Archive

Darzalex in combination with lenalidomide and dexamethasone was approved as a first-line treatment for multiple myeloma patients who are ineligible for autologous stem cell transplant.

Gottlieb’s knowledge of the regulatory and political landscape will be a boon for Pfizer as it dives deeper into oncology.

The company is working on developing therapies for neuropsychiatric diseases. Karuna is expecting data from a Phase II clinical trial later this year of KarXT xanomeline/trospium chloride, a muscarinic receptor modulator, to treat acute psychosis associated with schizophrenia.

Draper, based in Cambridge, Massachusetts, signed a tissue model development deal with Bristol-Myers Squibb. The companies will collaborate on developing a unique liver tissue model to screen drugs for toxicity.

The U.S. Food and Drug Administration (FDA) gave Alexion Pharmaceuticals a thumbs-up for Soliris (eculizumab) to treat neuromyelitis optica spectrum disorder (NMOSD) in adults that express a specific biomarker.

Using human induced pluripotent stem cells (iPSCs), researchers with Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California, were able to grow natural-looking hair that grows through the skin.

Four bills aimed at lowering prescription drug prices were advanced out of the U.S. Senate Judiciary Committee this week and will head to a vote on the Senate floor.

Exiting the last week of June and heading into July, a number of companies announced results from ongoing clinical trials. Here’s a look.

Researchers discovered a pathway that helps regulate inflammation and also prevents the buildup of toxic proteins related to Alzheimer’s.

Saluda Medical Pty Limited announced that it has secured $75 million in equity financing from Boston Scientific Corporation and Redmile Group LLC to fund the final stages of development through commercialization of its Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation System for the treatment of chronic intractable pain of the trunk and limbs.